UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of February 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

On February 923, 2026, Ascentage Pharma Group International issued a press releases entitled “Ascentage Pharma to Participate in ~~Guggenheim Emerging~~Three ~~Outlook:~~Upcoming ~~Biotech~~Investor ~~Summit 2026~~Conferences”. A copy of the press release is furnished as Exhibit 99.1.

INDEX TO EXHIBITS

Exhibit
Number		Exhibit Title
99.1		Press Release dated February 923, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: February 9, 2026	/s/ Dajun Yang
Date: February 23, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

Filing Compare · ASCENTAGE PHARMA GROUP INTERNATIONAL